Engraftment Syndrome after Allogeneic Hematopoietic Cell Transplantation Predicts Poor Outcomes  by Chang, Lawrence et al.
Biol Blood Marrow Transplant 20 (2014) 1407e1417Biology of Blood and
Marrow Transplantation
journal homepage: www.bbmt.orgEngraftment Syndrome after Allogeneic Hematopoietic Cell
Transplantation Predicts Poor OutcomesLawrence Chang 1, David Frame 2, Thomas Braun 3, Erin Gatza 1, David A. Hanauer 4,5,
Shuang Zhao 6, John M. Magenau 7, Kathryn Schultz 8, Hemasri Tokala 9, James L.M. Ferrara 1,
John E. Levine 1, Pavan Reddy 7, Sophie Paczesny 10, Sung Won Choi 1,*
1Department of Pediatrics, Division of Pediatric Hematology-Oncology, Blood and Marrow Transplantation Program, University of Michigan, Ann Arbor, Michigan
2College of Pharmacy, University of Michigan, Ann Arbor, Michigan
3Department of Biostatistics, University of Michigan, Ann Arbor, Michigan
4Department of Pediatrics, Division of General Pediatrics, University of Michigan, Ann Arbor, Michigan
5 Informatics Core of the Comprehensive Cancer Center, University of Michigan, Ann Arbor, Michigan
6University of Michigan Medical School, University of Michigan, Ann Arbor, Michigan
7Department of Internal Medicine, Division of Hematology-Oncology, Blood and Marrow Transplantation Program, University of Michigan, Ann Arbor, Michigan
8Department of Pharmacy, Rush University Medical Center, Chicago, Illinois
9Department of Internal Medicine, Michigan State University, East Lansing, Michigan
10Department of Pediatric Hematology-Oncology, Indiana University, Indianapolis, IndianaArticle history:
Received 9 May 2014
Accepted 22 May 2014
Key Words:
Engraftment syndrome
Hematopoietic cell
transplantation
Cytokine stormFinancial disclosure: See Acknowle
* Correspondence and reprint re
and Marrow Transplantation Pro
Medical Center Drive, 5304 Cancer
E-mail address: sungchoi@umic
1083-8791/$ e see front matter 
http://dx.doi.org/10.1016/j.bbmt.20a b s t r a c t
Engraftment syndrome (ES), characterized by fever, rash, pulmonary edema, weight gain, liver and renal
dysfunction, and/or encephalopathy, occurs at the time of neutrophil recovery after hematopoietic cell
transplantation (HCT). In this study, we evaluated the incidence, clinical features, risk factors, and outcomes
of ES in children and adults undergoing ﬁrst-time allogeneic HCT. Among 927 patients, 119 (13%) developed
ES at a median of 10 days (interquartile range 9 to 12) after HCT. ES patients experienced signiﬁcantly higher
cumulative incidence of grade 2 to 4 acute GVHD at day 100 (75% versus 34%, P < .001) and higher nonrelapse
mortality at 2 years (38% versus 19%, P < .001) compared with non-ES patients, resulting in lower overall
survival at 2 years (38% versus 54%, P < .001). There was no signiﬁcant difference in relapse at 2 years (26%
versus 31%, P ¼ .772). Suppression of tumorigenicity 2, interleukin 2 receptor alpha, and tumor necrosis factor
receptor 1 plasma biomarker levels were signiﬁcantly elevated in ES patients. Our results illustrate the clinical
signiﬁcance and prognostic impact of ES on allogeneic HCT outcomes. Despite early recognition of the syn-
drome and prompt institution of corticosteroid therapy, outcomes in ES patients were uniformly poor. This
study suggests the need for a prospective approach of collecting clinical features combined with correlative
laboratory analyses to better characterize ES.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Hematopoietic cell transplantation (HCT) is deﬁnitive
therapy for malignant and nonmalignant indications [1].
Despite improved outcomes over the past decade, non-
relapse mortality (NRM) is approximately 10% to 30% in the
ﬁrst year after HCT [2]. Engraftment syndrome (ES) is
a clinical condition of fever, rash, pulmonary edema, weight
gain, liver and renal dysfunction, and/or encephalopathydgments on page 1415.
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14.05.022occurring at the time of neutrophil recovery after HCT [3].
Although this syndrome can have a self-limited course, it has
the potential to progress to multiorgan dysfunction and
death [4,5].
A lack of consensus in both criteria and nomenclature of
ES has resulted in a wide range of reported incidences
between 6% and 82% in allogeneic HCT [6-22]. This is likely
affected by the heterogeneity of center-speciﬁc deﬁnitions of
ES. Furthermore, whether ES and graft-versus-host disease
(GVHD) are distinct syndromes in the allogeneic context
remains unclear [6,7,10,15,17,22]. The prognostic impact of ES
on outcomes, such as GVHD, relapse, NRM, and survival, has
not been well characterized. Although the underlying path-
ogenesis of ES remains poorly understood, inﬂammatory
mediators likely contribute to its development [3,21]. TheTransplantation.
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steroid therapy) to capillary leak syndrome or GVHD has,
therefore, made their distinction difﬁcult in the allogeneic
setting [3]. In fact, ES has commonly been described as a
cytokine storm condition [3] or hyperacute GVHD [10].
The criteria for ES are predominantly characterized by
fever and rash [6-22]. Spitzer’s criteria is the most widely
described [3], with variations related to the duration of the
neutrophil peri-engraftment period for associated symptoms
[7,8,11-15]. Risk factors noted to be associated with ES
include myeloablative conditioning [10,17,18,20], unrelated
donor [6,7,10], female recipient [9], use of granulocyte colo-
nyestimulating factor [12], number of prior chemotherapy
regimens received [10], higher cell concentration infused at
transplantation [12,15,22], donor-recipient HLA disparity
[13], and age [9,13,17].
In this study, we systematically explored the deﬁnition,
distribution, and outcomes of ES. We hypothesized that
allogeneic HCT recipients who develop ES would have
increased risk of GVHD and NRM, leading to inferior survival
compared with patients who do not develop ES. We con-
ducted a retrospective analysis of clinical characteristics and
outcomes of ES after allogeneic HCT over a 9-year period. We
also measured plasma biomarkers on samples that were
collected prospectively in the early peri-transplantation
period at day 0 and day 14 to determine their role in the
development of ES.
METHODS
Literature Review of Engraftment Syndrome
Consensus on the diagnostic criteria of ES has not been achieved.
A literature review of ES after allogeneic HCT was, therefore, conducted to
identify the most commonly reported diagnostic criteria and risk factors.
PubMed and Google Scholar were used to search for peer-reviewed litera-
ture published in the English language between July 2001 and August 2013.
The following terms were included in the search: engraftment syndrome
[3,23], cytokine storm [24,25], pre-engraftment [14,15,26], peri-engraftment
respiratory distress [27], multiple organ dysfunction [3], capillary leak
[4,28], autoaggression syndrome [25], diffuse alveolar hemorrhage [29], and
hyperacute GVHD [7,10]. Case reports and nonallogeneic HCT patient pop-
ulations were excluded.
The PubMed/Google Scholar search was performed in September 2013.
The initial search resulted in 40 articles. Twenty-two were excluded
immediately because they were autologous (18), autologous and allogeneic
(3), or syngeneic (1) studies. Two authors (L.C. and S.W.C.) independently
screened all of the papers; 18 ES manuscripts published between 2001 and
2013 were identiﬁed, which were restricted to allogeneic studies
(Supplementary Table S1). L.C. and S.W.C. read the full text of the 18 man-
uscripts. Study populations ranged between 44 and 809.
Deﬁnition of ES
L.C. and S.W.C. analyzed each of the 18 papers (Supplementary Table S1)
and iteratively developed a consensus to capture the commonalities of the
ES criteria derived from the literature. ES was deﬁned in this study popu-
lation by the major and minor criteria outlined by Spitzer [3]. The 3 major
criteria are noninfectious fever, erythroderma involving 25% body surface
area not attributed to medication, and noncardiogenic pulmonary edema.
The 4 minor criteria are total bilirubin 2 mg/dL or transaminases 2 times
normal levels, serum creatinine 2 times baseline, weight gain 2.5% of
baseline body weight, or unexplained encephalopathy. ES diagnosis was
made when all 3 major criteria were met or 2 major plus 1 minor criterion
were met. Diagnosis was expanded to uncouple Spitzer’s time criterion of ES
onset within 96 hours of neutrophil engraftment [20] and to include pa-
tients who developed 2 major Spitzer criteria (without the need for minor
criteria) and were started on systemic steroids for presumed ES. ES onset
was established as the day after HCT that a patient ﬁrst satisﬁed at least
2 major criteria.
Study Design
A retrospective cohort study of 988 consecutive allogeneic HCT was
conducted between January 1, 2004 and December 31, 2012. The study was
approved by the University of Michigan Institutional Review Board(HUM0024071: “Determination of risk factors and outcomes of allogeneic
transplant recipients with engraftment syndrome”). Only ﬁrst-time alloge-
neic HCT recipients were included. Forty-one patients with prior allogeneic
HCT were, therefore, excluded. The primary outcome of the study was
incidence of ES after allogeneic HCT. Death and relapse before day 21 after
HCT were treated as competing events. Primary graft failure determined by
bonemarrow biopsy was also treated as a competing event. Twenty patients
with competing events (death, relapse, or primary graft failure) were
excluded from the analyses, yielding a study population of 927 patients.
Secondary study outcomes included length of hospital stay and incidences
of acute GVHD, relapse, NRM, and survival.
Length of hospitalizationwas deﬁned as the time between admission for
transplantation and discharge. Acute GVHD was assessed weekly using the
modiﬁed Glucksberg criteria (Supplementary Table S2) [30]. Skin biopsies
were performed (where clinically possible) on patients who presented with
rash. Patients met ES criteria only if pathology was not diagnostic for GVHD.
The date of onset of acute GVHD was not the same as the date of onset of ES
[19]. In cases when ES progressed to acute GVHD without an intervening
period of symptom resolution, the onset of acute GVHDwas identiﬁed as the
date corticosteroid dosing was increased or new GVHD symptoms occurred.
Biopsies were obtained in all cases to conﬁrm the diagnosis of acute GVHD of
the skin or gut. Relapse was considered a competing risk for acute GVHD.
Relapse superseded all other causes of death. Acute or chronic GVHD su-
perseded all nonrelapse/nonprogression causes of death.
Demographic and Transplantation Characteristics
Demographics, including age at transplantation, gender, race, ethnicity,
disease at transplantation, and number of prior autologous transplantations,
were collected for each patient and recorded in the integrated blood and
marrow transplantation (BMT) clinical research database. Transplantation
data, including donor stem cell source, donor type (related, unrelated),
donor gender, HLA matching, cytomegalovirus status of donor and recipient
at transplantation, ABO Rh blood types of donor and recipient, conditioning
regimen, CD34þ cell dose infused for transplantation, GVHD prophylaxis
regimen, and time to engraftment, were also collected and recorded.
Granulocyte colonyestimulating factor was started from day 6 to promote
neutrophil engraftment. Neutrophil engraftment was deﬁned as the ﬁrst of
3 consecutive days with absolute neutrophil count 500/mm3. ABO in-
compatibility was deﬁned as previously described [31], and full details are
provided in Supplementary Table S3.
Electronic Medical Record Search Engine (EMERSE): Chart Review
Data abstraction was supported by the use of the University of Michigan
EMERSE, which has been used for a wide variety of peer-reviewed publi-
cations [32,33], and provides software features to comprehensively scan all
clinical documents from our electronic health record (EHR) system for key
words and phrases to ensure that even rarely mentioned events are detec-
ted. In the current study, a collection of 82 search terms were used, which
was iteratively developed based on manual reviews of clinical notes as well
as the clinical expertise of the research team. Terms included aforemen-
tioned synonyms for ES and component symptoms, such as fever and rash
(complete list of search terms can be found in Supplementary Table S4).
Every patient ﬂagged by EMERSE underwent further chart review. Chart
review involved a checklist of the workup of Spitzer symptoms, including
infectious etiologies for fevers, radiographs, and oxygen saturation for pul-
monary edema, medications associated with rashes, skin biopsies, etiologies
for encephalopathy, laboratory measures, weight indices, and tracking the
diagnosis for the duration of the entire transplantation admission.
Competing differentials, such as drug reaction, infection, GVHD, veno-
occlusive disease, and idiopathic pneumonia syndrome that would pre-
clude diagnosing ES, were also identiﬁed and excluded. Development of
ES was ﬁrst evaluated independently of GVHD status. For patients who
developed GVHD, presentations of ES occurring after GVHD onset date were
excluded.
Steroid Therapy
Supportive care therapies, including anti-infectives and blood product
transfusions, were administered according to institutional clinical practice
guidelines. There was no uniform approach in the management of ES.
Although systemic corticosteroid therapy was utilized in the majority of
cases, physician preference determined the starting dose and tapering
schedule. The EHR was used to collect systemic corticosteroid dosing for a
28-day period from initial steroid administration. All formulations were
converted to methylprednisolone equivalent dosing (mg/kg/day).
Plasma Biomarkers
Day 0 and day 14 post-HCT blood samples were collected prospectively
from patients who underwent transplantation between January 2004 and
L. Chang et al. / Biol Blood Marrow Transplant 20 (2014) 1407e1417 1409May 2010, with informed consent in agreement with the Declaration of
Helsinki. Samples were collected in heparin-containing vacutainer tubes
(Becton Dickinson, Franklin Lakes, NJ) and underwent Ficoll (Amersham,
Piscataway, NJ) gradient centrifugation to separate out plasma. Suppression
of tumorigenicity 2 (ST2), interleukin 2 receptor alpha (IL2Ra), and tumor
necrosis factor receptor 1 (TNFR1) plasma concentrations were measured in
duplicate via enzyme-linked immunosorbent assays, as previously
described [34-36], and according to the manufacturer protocol (R&D Sys-
tems, Minneapolis, MN). Absorbances were read using a SpectraMax M2e
plate reader (Molecular Devices, Sunnyvale, CA). The integrated BMT clinical
research database, which contained demographic and transplantation
characteristics and clinical outcomes (GVHD, NRM, relapse, and survival)
gathered from transplantation patients, was readily linked to speciﬁc
plasma biomarker samples that were collected and stored in accordance to
the institution review boardeapproved protocol HUM43287, to ensure
patient conﬁdentiality.
Statistical Analysis
Analysis was done using R 3.02 (GNU General Public License) and SAS
9.3 (SAS Institute, Cary, NC). The level of statistical signiﬁcance was deﬁned
at a ¼ .05. Demographics of all ﬁrst-time allogeneic HCT patients were
summarized for the overall population and according to development of ES.
Counts and percentages were determined for categorical variables. Median,
range, and interquartile range (IQR) were determined for continuous
variables.
Univariate analysis of ES with respect to each demographic and
transplantation characteristic was modeled using logistic regression on the
primary event of interest, ES. Statistically signiﬁcant factors were selected
for the multivariate analysis and then pared down via a stepwise logistic
regression. Incidences of GVHD, relapse, NRM, and survival were stratiﬁed
between ES and non-ES patients. Cumulative incidences with competing
risks were determined using the Fine-Gray method [37] and compared
using the K-sample test described by Gray [38]. Overall survival was
compared with Kaplan-Meier [39]. As GVHD, death, and graft failure were
competing events before day 21, the incidence of ES was assessed in our
study population. We analyzed the relationship between ES and GVHD
severity by determining the incidence of ES for each GVHD grade by
logistic regression. ES incidences stratiﬁed by GVHD grade were compared
pairwise with Bonferroni correction of statistical signiﬁcance .005, pro-
ducing 10 comparisons. An analysis of trend was performed by modeling
the incidence of ES via logistic regression of GVHD severity. Cox regression
analysis was performed to assess the baseline steroid dose on risk of acute
GVHD, NRM, and overall survival.
The absolute change in plasma ST2, TNFR1, and IL2Ra levels from day
0 to day 14 were calculated. A 2-sample t-test was used to compare the
difference in the mean change in levels between ES and non-ES patients.
Plasma samples were analyzed only among individuals who had samples
collected at both day 0 and day 14, reﬂecting the time frame when the
majority of ES develops. The potential concern for missing plasma
biomarker data was addressed in a sensitivity analysis by comparing base-
line demographic and transplantation characteristics of the ST2, IL2Ra, and
TNFR1 biomarker subpopulations with the total population. There were no
signiﬁcant differences in nearly all patient characteristics (Supplementary
Table S5).
RESULTS
Patient and Transplantation Characteristics of Study
Population
The study population had a median age of 51 years (IQR,
31 to 58; range, 0 to 73) and was comprised predominantly
of adults (>18 years old, 85%), males (60%), and Caucasians
(90%). Ninety-four percent of patients had hematological
malignancies. Patients received HLA-matched related (44%),
mismatched related (3%), matched unrelated (37%),
mismatched unrelated (13%), and double-mismatched
transplants (3%, double cord). HCT was performed using
cells from peripheral blood (81%), bone marrow (14%), and
cord blood (5%). Sixty-three percent of patients were
conditioned with myeloablative regimens (23% of which
included total body irradiation [TBI]  1200 cGy) and 37%
with reduced-intensity regimens, according to the 2009
American Society for Blood and Marrow Transplantation
working deﬁnitions [40]. Seven percent were conditioned
with regimens that involved antihuman T cell antibody(antithymocyte globulin/thymoglobulin or alemtuzumab).
CD34þ cells were infused at a median concentration of
5.4  106 cells/kg (IQR, 4.3  106 to 6.7  106; range,
6.4  106 to 1.75  107). Engraftment occurred on median
day 12 (IQR, 11 to 13; range, 4 to 64) after transplantation.
These characteristics are stratiﬁed by ES outcome in Table 1.
Incidence of Engraftment Syndrome
A total of 927 consecutive patients met the inclusion
criteria of ﬁrst-time allogeneic HCT with no competing risk
of death, relapse, or primary graft failure before day 21 after
HCT (Figure 1). Among these 927 patients, 119 (13%) met our
ES criteria. ES onset occurred at median day 10 (IQR, 9 to 12;
range, 6 to 21) after HCT. The distribution of ES signs and
symptoms are shown in Table 2. Fever was present in 100% of
ES patients, followed by nonmedication-related rash (84%)
and noncardiogenic pulmonary edema or hypoxia (54%).
Fifty-ﬁve ES patients underwent skin biopsy. The pathology
ﬁndings included vascular interface dermatitis/perivascular
inﬂammation (n ¼ 27), minimal histologic change/near
normal skin (n ¼ 16), or epidermal dysmaturation/dysker-
atosis (n ¼ 12).
Risk Factors for Engraftment Syndrome
Demographic factors and transplantation characteristics
that showed signiﬁcantly higher risk of ES in the univariate
analysis included younger age recipients (P < .001), male
recipients (P ¼ .013), male-male donor-recipient combina-
tions (P ¼ .033), unrelated donors (P < .001), ABO major
incompatibility (P ¼ .025), myeloablative conditioning
(P < .001), and TBI  1200 cGy (P < .001) (Table 1). Bone
marrow and peripheral blood transplantations each showed
11% incidence of ES over the study period comparedwith 41%
in cord transplantations (with up to 52% in double cord), the
latter source was signiﬁcantly associated with ES develop-
ment (P< .001). The stepwise multivariate logistic regression
modeled on statistically signiﬁcant characteristics from the
univariate analysis identiﬁed 3 signiﬁcant predictors associ-
ated with ES outcome: gender (higher probability among
male recipients, P¼ .006), conditioning (higher probability in
myeloablative conditioning and even higher with TBI-based
1200 cGy conditioning, P < .001), and donor source
(lower probability for matched related donors than any other
source, P < .001).
Biomarker Analyses
Plasma levels were evaluated at days 0 and 14, the period
reﬂecting the highest risk for development of ES. Signiﬁcantly
higher mean increases in biomarker levels were seen in ES
patients compared with non-ES patients for ST2, IL2Ra, and
TNFR1 (3673 versus 142 picogram (pg)/mL, P < .001; 1869
versus 910 pg/mL, P < .001; and 3981 versus 2295 pg/mL,
P ¼ .001, respectively) (Figure 2).
Response to Therapy
Among the 119 ES cases, 94 (79%) were treated with
systemic corticosteroid therapy (Figure 1). The median
starting dosewas 1.1mg/kg/day (IQR .9 to 2.0; range .2 to 4.0)
and fever resolved promptly in most cases after treatment
initiation. Complete resolution of all ES symptoms was ach-
ieved in 9 of the 94 treated patients (10%), who did not
develop later acute GVHD. Three patients (3%) died as a direct
result of ES. Seventy of the 94 patients (74%) progressed to
grade 2 to 4 acute GVHD with a median time of 28 days (IQR,
21 to 32; range, 10 to 87) despite a median dose of
Table 1
Demographic and Transplantation Characteristics
Patient Characteristics ES Non-ES Univariate P Value
Total 119 808*
Age, yr 44 (0-69, 22-69) 52 (0-73, 34-58) <.001
Pediatric (18 yr old) 25 (21.0%) 111 (13.7%)
Adult 94 (79.0) 697 (86.3)
Gender
Male 83 (69.7) 473 (58.5) .013
Female 36 (30.3) 345 (42.7)
Race/Ethnicityy
White (non-Hispanic) 107 (89.9) 731 (90.5) .848
All other 12 (10.1) 77 (9.5)
Disease
Malignant 115 (96.6) 755 (93.4) .086x
Non-Hodgkin lymphoma 27 (22.7) 122 (15.1)
Acute myelogenous leukemia 32 (26.9) 289 (35.8)
Acute lymphoblastic leukemia 30 (25.2) 100 (12.4)
Myelodysplastic syndrome 6 (5.0) 76 (9.4)
Multiple myeloma 4 (3.4) 52 (6.4)z
Chronic lymphoblastic lymphoma 8 (6.7) 36 (4.5)
Chronic myelogenous leukemia 4 (3.4) 20 (2.5)
Myeloﬁbrosis e 21 (2.6)
Myeloproliferative disorder e 17 (2.1)
Hodgkin lymphoma 2 (1.7) 15 (1.9)
Biphenotypic leukemia 1 (.8) 7 (.9)
Histiocytic sarcoma 1 (.8) e
Nonmalignant 4 (3.4) 53 (6.6)
Severe aplastic anemia 1 (.8) 23 (2.8)
Sickle cell disease e 8 (1.0)
Thalassemia e 5 (.6)
Familial erythrophagocytic lymphohistiocytosis 1 (.8) 2 (.2)
Paroxysmal nocturnal hemoglobinuria e 2 (.2)
Severe combined immunodeﬁciency e 3 (.4)
Severe congenital neutropenia 1 (.8) 1 (.1)
X-linked Lymphoproliferative syndrome e 3 (.4)
Immunodysregulation polyendocrinopathy enteropathy
X-linked syndrome
e 1 (.1)
Dyskeratosis congenita e 2 (.2)
Osteopetrosis e 1 (.1)
Congenital dyserythropoietic anemia e 1 (.1)
Glanzmann thrombasthenia e 1 (.1)
Chronic granulomatous disease 1 (.8) e
Prior autologous transplantations
0 106 (89.1) 730 (90.3) .782
1 12 (10.1) 68 (8.4)
2 1 (.8) 10 (1.2)
Transplantation type/source
Overall
PB 84 (70.6%) 661 (81.8) <.001
BMk 15 (9.2) 118 (14.6)
CB 20 (16.8) 29 (3.6)
Related
PB 11 (9.2) 367 (45.4) .972
BMk 2 (1.7) 59 (7.3)
CB e 1 (0.1)
Unrelated
PB 73 (61.3) 294 (36.4) .002
BM 13 (10.9) 59 (7.3)
CB 20 (16.8) 28 (3.5)
Gender pairing donor-recipient{
Overall
Male-male 60 (50.4) 302 (37.4) .033
Male-female 24 (20.2) 215 (26.6)
Female-male 23 (19.3) 171 (21.2)
Female-female 11 (9.2) 120 (14.9)
HLA matching
Matched related 8 (6.7) 404 (50.0) <.001
Mismatched related 5 (4.2) 23 (2.8)
Matched unrelated 59 (49.6) 286 (35.4)
Mismatched unrelated 34 (28.6) 83 (10.3)
Mismatched-mismatched unrelated 13 (10.9) 12 (1.5)
CMV#
Single donor
Both negative (R- D-) 41 (34.5) 251 (31.1) .225
Recipient negative (R- Dw) 14 (11.8) 82 (10.1)
(Continued on next page)
L. Chang et al. / Biol Blood Marrow Transplant 20 (2014) 1407e14171410
Table 1
(continued)
Patient Characteristics ES Non-ES Univariate P Value
Donor negative (Rw D-) 29 (24.4) 236 (29.2)
Both non-negative (Rw Dw) 22 (18.5) 227 (28.1)
Double cord (Recipient [R] Donor [D1] Donor [D2])
Recipient negative (R- Dw Dw) 5 (4.2) 3 (.4)
Recipient positive (Rþ Dw Dw) 8 (6.7) 9 (1.1)
ABO blood type matching**
Single donor
Match 53 (44.5) 470 (58.2) .025
Bidirectional 5 (4.2) 36 (4.5)
Minor 18 (15.1) 160 (19.8)
Major 30 (25.2) 130 (16.1)
Double cord (compatibility between R-D1 R-D2 D1-D2)
Match 2 (1.7) 5 (0.6)
Any incompatibility 11 (9.2) 7 (0.9)
Rh blood type matching**
Single donor
Match 85 (71.4) 643 (79.6) .973
Major 10 (8.4) 73 (9.0)
Minor 11 (9.2) 89 (11.0)
Double cord
Match 9 (7.6) 7 (0.9)
Any incompatibility 4 (3.4) 5 (0.6)
Conditioning intensityyy
Myeloablative 91 (76.5) 494 (61.1) <.001
Total body irradiation  1200 cGy
Yes 35 (29.4) 98 (12.1)
No 56 (47.1) 396 (49.0)
Reduced intensity 28 (23.5) 314 (38.9)
Conditioning antihuman T cell antibody
Overall
ATG/Thymoglobulin (Genzyme, Cambridge, MA) 4 (3.4) 54 (6.7) .217
Campath (Pﬁzer, NY, NY) e 7 (.9)
None 115 (96.6) 747 (92.5)
Myeloablative
ATG/Thymoglobulin 3 (2.5) 21 (2.6) >.999
Campath e e
None 88 (73.9) 473 (58.5)
Reduced intensity
ATG/Thymoglobulin 1 (.8) 33 (4.1) .347
Campath e 7 (.9)
None 27 (22.7) 274 (33.9)
GVHD prophylaxis
Calcineurin inhibitor plus methotrexate 71 (59.7) 482 (59.7) .383
Calcineurin inhibitor plus mycophenolate mofetil 48 (40.3) 304 (37.6)
Calcineurin inhibitor alone e 4 (0.5)
Other e 18 (2.2)
CD34þ (106 cells/kg) 5.2 (.17-17.5, 3.6-6.7) 5.4 (.06-17.5, 4.4-6.8) .159
Total nucleated cells (107 cells/kg) cord transplantations only 5.3 (2.9-46.0, 3.7-7.3) 5.1 (1.4-7.6, 3.9-9.9) .772
Neutrophil engraftment day 12 (6-35, 11-13.5) 12 (4-64, 11-13) .718
PB indicates peripheral blood; BM, bone marrow; CB, cord blood; CMV, cytomegalovirus; R, recipient; D, donor; ATG, antithymocyte globulin.
Data presented are count (%) or median (range, interquartile range).
* Twenty patients were excluded because of relapse, death, or graft failure before day 21, which are competing events to developing ES.
y Race/ethnicity other refers to biracial and/or Alaskan and Native American.
z One non-ES patient had plasma cell leukemia, which was grouped with multiple myeloma.
x Comparison between malignant and nonmalignant categories.
k Two patients received bone marrow þ related cord blood from the same donor but are categorized as BM.
{ Among double cord transplantations with a male and a female donor, the gender listed is the predominant/majority donor once engrafted, as determined by
cytogenetics. In 1 peripheral blood transplantation, the donor gender was not disclosed.
# w wild refers to any possible CMV result þ, , equivocal, or unknown. CMV status was not compared among double cord transplants
** Blood type compatibility for double cords is reported in order of matching between recipient-donor1, recipient-donor2, and donor1-donor2. ABO and Rh
blood type compatibility was not statistically compared among double cord transplants.
yy Full (myeloablative) and reduced (nonmyeloablative) -intensity conditioning. Three different comparisons were done in the comparing conditioning with all
3 resulting in P value <.001: (1) all full intensity versus all reduced intensity, (2) TBI 1200 cGy versus TBI <1200 cGy (all reduced excluded), and (3) TBI
1200 cGy versus TBI <1200 cGy versus reduced intensity.
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0 to 3.7) at that time point (Figure 1). Among the 25 patients
who were not initiated on corticosteroid treatment for ES, 19
(75%) progressed to grade 2 to 4 acute GVHD with a median
time of 26 days (IQR, 21 to 29; range, 16 to 84) (Figure 1).
The starting doses and tapering schedules varied widely
among ES patients, which indicated that uniform practiceswere not performed among treating physicians. In efforts to
determine the rationale for corticosteroid therapy, the
distribution of symptoms were evaluated according to
starting dose (no steroids, <1.5 mg/kg/day, 1.5 mg/kg/
day). The distribution of fever, rash, and pulmonary edema
were consistent across treatment groups. However, mean
creatinine and percent weight increase were higher in
Figure 1. Distribution of study patients and outcomes. Steroids refer to engraftment syndrome (ES) treatment with systemic corticosteroids. *Graft-versus-host
disease (GVHD) refers to maximum acute GVHD grade. yES includes patients who met only 2 major Spitzer criteria but no minors, yet were advanced on systemic
steroids in addition to those who also fulﬁlled the Spitzer criteria of 3 majors or 2 majors plus 1 minor criteriondall without the 96-hour time criterion for these signs
and symptoms.
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(Table 2).
Clinical outcomes of grade 2 to 4 acute GVHD, NRM, and
overall survival were evaluated as a function of starting
steroid dose dichotomized above or below 1.5 mg/kg/day.
The resulting hazard ratios suggested a trend toward lower
risk of grade 2 to 4 acute GVHD, higher NRM, and decreased
survival with baseline steroid dose above 1.5 mg/kg/day.
These observations were not found to be statistically signif-
icant (Figure 3). Similar ﬁndings were observed when base-
line steroid doses were treated as a continuous predictor
(data not shown).
Consequences of Development of Grade 2 to 4 Acute
GVHD, NRM, and Survival
The median follow-up of the study was 49 months (IQR,
28 to 79; range, 2.7 to 117.7) from transplantation dateTable 2
ES Criteria Distribution
Distribution n (%) among ES Values a
No Ster
N 119 25
Fever T 38C 119 (100%) 25 (100
Rash 25% body surface area 100 (84) 23 (92)
Pulmonary edema 64 (54) 15 (60)
Total bilirubin >2 mg/dL 29 (24) 1.31
Creatinine >2 mg/dL 9 (8) .84
Weight increase > 2.5% baseline 91 (77) 2.7%*
Encephalopathy 15 (13) 4 (16)
Systemic corticosteroids 94 (79)
No systemic corticosteroids 25 (21)
T indicates temperature.
* Values are mean percent increase in weight from baseline admission weight.(Table 3). Median hospital length of stay was 30 days (IQR, 24
to 45; range, 0 to 154) for ES patients and 23 days (IQR, 21 to
28; range, 0 to 175) for non-ES patients (P < .001). The main
causes of deaths in ES patients were relapse (35%), acute
GVHD (40%), and chronic GVHD (17%) compared with 54%,
17%, and 22% in non-ES patients, respectively (Table 3). The
pairwise comparisons between GVHD grades showed sig-
niﬁcant differences in probability of ES between grades 1 and
4 acute GVHD (P < .005, Supplementary Table S6). There
were no signiﬁcant differences among grades 2, 3, and
4 acute GVHD. The analysis for trend between ES incidence
and GVHD grade showed that patients with more severe
acute GVHD had higher probability of having had ES
(P < .001, Supplementary Table S6).
ES patients experienced a signiﬁcantly higher cumulative
incidence of grade 2 to 4 acute GVHD at day 100 (75% versus
34%, respectively, P < .001) and higher NRM at 2 years (38%mong ES (Count or Mean)
oids Steroids <1.5 mg/kg/d Steroids 1.5 mg/kg/d
53 41
%) 53 (100%) 41 (100%)
44 (83) 33 (80)
28 (53) 21 (51)
1.01 1.67
.93 .98
4.5%* 5.7%*
7 (13) 4 (10)
Figure 2. Biomarker Studies. Shown are- ES versus No ES. Day 0 and day
14 mean change in plasma levels of (A) suppression of tumorigenicity 2 (ST2),
- n ¼ 43, n ¼ 252; (B) interleukin 2 receptor a (IL2Ra), - n ¼ 64,
n ¼ 165; (C) tumor necrosis factor receptor 1 (TNFR1), - n ¼ 64, n ¼ 165.
Figure 3. Steroid Data. Median methylprednisolone equivalent dosing course over tim
mg/kg/d (dashed) at onset of engraftment syndrome (ES). The corresponding table s
L. Chang et al. / Biol Blood Marrow Transplant 20 (2014) 1407e1417 1413versus 19%, respectively, P < .001), resulting in lower overall
survival at 2 years (38% versus 54%, respectively, P < .001)
compared with non-ES patients (Figure 4). There was no
signiﬁcant difference in relapse at 2 years (26% versus 31%,
respectively, P¼ .772) (Figure 4). When patients were further
analyzed on the basis of grade 2 to 4 acute GVHD, ES patients
experienced higher NRM (42%) and lower survival (39%) at
2 years compared with non-ES patients (31% and 44%)
(Supplementary Table S7). Among ES patients who devel-
oped no GVHD or only grade 1 GVHD, high NRM (27%) and
low survival (35%) were still seen. This contrasted with the
favorable NRM (11%) and survival (61%) of non-ES patients,
who developed no GVHD or only grade 1 GVHD
(Supplementary Table S7) at 2 years.DISCUSSION
To our knowledge, this is the largest population evaluated
for ES including children and adults and provides
a comprehensive assessment of ES among allogeneic HCT
recipients. We used the EMERSE system with an extensive
list of 82 search terms and phrases to ensure that all men-
tions of “engraftment syndrome,” including a constellation of
clinical symptoms, were identiﬁed in the EHR. This approach
allowed high sensitivity in ﬂagging all candidate patient
records to review for ES. Four independent researchers
conducted a thorough chart review to minimize potential
measurement error. Consensus was reached on all discrep-
ancies. This study did not identify the distribution of minor
ES criteria in the entire population (non-ES); therefore, the
level of association of each criterion could not be assessed to
validate the Spitzer criteria.
The literature reviewed suggests that consensus on the
diagnostic criteria of ES after allogeneic HCT has yet to be
established, as the clinical symptomatology and timing
remain unclear. Although the Spitzer criteria remain among
the more accepted deﬁnitions, recent studies, including ours,
have favored relaxing the time criterion around neutrophil
engraftment. “Pre-engraftment syndrome” and ES have been
shown to be indistinguishable in outcome analyses [8] and in
distribution of Spitzer criteria [3], leading to a proposal of
“peri-engraftment syndrome” to encompass any time after
transplantation for ES to occur [20]. Other studies have also
used a broader time range than allowed by Spitzer [41-43],e dichotomized by baseline starting dose of 1.5 mg/kg/day (solid) and <1.5
hows hazard ratios of clinical outcomes comparing this baseline dichotomy.
Table 3
Clinical Outcomes
Outcome ES Non-ES
Follow-up time, mo 63.7 (16.5-116.9, 35.0-101.7) 47.8 (2.7-117.7, 26.0-75.6)
Hospital length of stay, d 30 (0-154, 24-44.5) 23 (0-175, 21-28)
Acute GVHD*
Yes 100 (84.0%) 370 (45.8%)
1 13 (10.9) 98 (12.1)
2 40 (33.6) 157 (19.4)
3 18 (15.1) 52 (6.4)
4 29 (24.4) 63 (7.8)
No 19 (16.0) 438 (54.2)
ES to Acute GVHD 2-4, d 27 (13-84, 21-31.5) NA
Steroids 27.5 (13-69, 21-69)
No steroids 26 (19-84, 21-29)
Relapse
Yes 34 (28.6%) 291 (36.0%)
No 85 (71.4) 517 (64.0)
Survival
Alive 36 (30.3%) 364 (45.1%)
Dead 83 (69.8) 444 (55.0)
Causes of death
Relapse 29 (34.94%) 241 (54.28%)
Acute GVHD 33 (39.76) 76 (17.12)
Chronic GVHD 14 (16.87) 94 (21.17)
Graft rejection or failure e 6 (1.35)
Idiopathic pneumonia syndrome e 8 (1.80)
Infectiony 1 (1.20) 6 (1.35)
Hepatic veno-occlusive disorder 1 (1.20) 4 (.90)
Lung cancer 1 (1.20) 2 (.45)
ES 3 (3.61) e
Cardiac event e 1 (.23)
Esophageal cancer e 1 (.23)
Myocardial infarct e 1 (.23)
Post-transplantation lymphoproliferative disorder e 1 (.23)
Pulmonary hypertension 1 (1.20) e
Small bowel obstruction e 1 (.23)
Unknown e 2 (.5)
Data presented are n (%) or median (range, IQR).
* Acute GVHD onset day 100 after transplantation and not after relapse, max grade shown.
y Among deaths from infection, only 1 ES patient died (pneumonia). Among non-ES patients, there was 1 culture-negative sepsis, 1 pneumonia leading to
sepsis, 3 bacterial, and 1 viral.
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recognized that steroid therapy may have been initiated in
a clinical course before completely satisfying the Spitzer
criteria and may have potentially affected further ES mani-
festations. We, therefore, included patients who met only
2 major criteria yet were started on steroids for the purpose
of treating ES.
The overall incidence of ES in this study (13%) was lower
than many previously reported estimates of ES
[7,8,12,14,15,17-19,22]. The strict criteria used herein may
have accounted for the lower incidence observed. It is
important to recognize that comparison between studies is
not straightforward, given the varied deﬁnitions of ES and the
heterogeneity on analysis of age-speciﬁc or disease-speciﬁc
populations. For example, if we selected only pediatric
patients (18 years old), the ES incidence herein of 18%
resembles the 17% observed in a previously reported pedi-
atric allogeneic study that uncoupled the time criterion [20].
It is also possible that if diarrheawere included as a criterion,
as previously described [44], the incidence of ES may have
been higher. This highlights the challenge of using center-
speciﬁc deﬁnitions and generalizing the ﬁndings.
In this study, we analyzed clinical risk factors for ES.
Using a stepwise multivariate model, the risk of ES was
signiﬁcantly higher among male recipients, those with
myeloablative conditioning with TBI  1200 cGy, and with
an unrelated donor HCT. Although high-dose TBI andunrelated donor HCT have previously been reported in
association with ES [6,7,10,17,18,20], gender-speciﬁc risk
factors have not been found to be associated with ES [13,14].
Only 1 study, which was conducted in the nonmyeloablative
setting, showed that being a female recipient was a poten-
tial risk factor from the multivariate logistic model that was
used. In their model, the covariates included were only
those occurring before the development of ES (age, gender,
and use of amphotericin B) [9]. Of note, recipient gender
was not found to be a signiﬁcant risk factor in the univariate
analysis. Future studies will need to explore this observation
and assess the role of recipient gender.
Given the small sample size of cord blood trans-
plantations in this study, we did not identify the use of cord
blood as a statistically signiﬁcant risk factor in the multi-
variate model. Nonetheless, our study conﬁrmed the high
incidence of ES after cord blood transplantation in
the univariate analysis (41% ES) [14,19,20,22]. A majority
of recently published reports describing pre-engraftment
syndrome after cord blood transplantation have been retro-
spective, single-institution reviews. However, ES is particu-
larly common in this setting and prospective, multicenter
studies are needed to better deﬁne the syndrome.
Our data show that ES patients were at high risk for
developing GVHD, supporting other recently published
studies [6,15,17,22]. It is also possible that ES can overlap or
coexist with GVHD. The distinction in the allogeneic setting
Figure 4. Clinical outcomes for engraftment syndrome (ES) and non-ES patients. Cumulative incidence of (A) acute GVHD grades 2 to 4, (B) overall survival,
(C) relapse, and (D) nonrelapse mortality.
L. Chang et al. / Biol Blood Marrow Transplant 20 (2014) 1407e1417 1415remains difﬁcult, particularly as the majority of ES patients
developed rash. ST2, IL2Ra, and TNFR1 biomarker levels,
previously described in GVHD [35,36,45], were signiﬁcantly
elevated in ES patients compared with non-ES patients.
These ﬁndings were not entirely surprising given the high
incidence of GVHD among our ES patients. Moreover, ES
patients experienced higher NRM and lower overall survival.
Interestingly, despite the use of corticosteroid therapy in this
high-risk group with high early post-HCT biomarker levels,
ES patients uniformly had poor outcomes. This is consistent
with ST2 as a marker for risk of therapy-resistant GVHD and
death [35]. An important limitation of our study was the
calendar-driven approach of plasma collection (day 0 and
14). Optimal sampling, such as ES onset, may have affected
the ﬁndings. Future studies should develop protocols of
event-driven samples to enhance the data.
Although stringent monitoring and early identiﬁcation of
high-risk ES patients may affect outcomes, the existing use of
ﬁrst-line corticosteroid therapy, even at high doses, did not
prove effective in reducing GVHD incidence in our study
population. An important limitation of this study is the
retrospective design and lack of information regarding
rationale for selection of baseline steroid dose and the sub-
sequent tapering schedule. These observations, therefore,
suggest the need to adopt a standard ES deﬁnition and
treatment strategy. A recent study incorporated corticoste-
roids within the GVHD prophylaxis to prevent ES, particularly
in high-risk settings, such as cord blood transplantations [20].
Another study suggested corticosteroid therapy 1 mg/kg/dayfor 3 days with no taper and close monitoring [14]. This is an
interesting strategy, particularly given the potential risk of
intense immunosuppression early after HCT that could lead
to increased opportunistic infections. Although corticoste-
roids are commonly used to treat the symptoms of ES,
a prolonged course of high-dose steroids as preemptive
strategy to prevent progression to GVHD is uncertain, as there
may be lack of response or a refractory nature to corticoste-
roids in this high-risk population. Indeed, the high ST2
biomarker levels found early after HCT in ES patients support
this possibility [35]. Potential preventive strategies to
improve transplantation outcome include novel agents that
target such biomarkers or other early proinﬂammatory
cytokines.
In summary, we show that ES is a signiﬁcant complication
after allogeneic HCT, resulting in longer length of hospital
stay, more severe GVHD, higher NRM, and lower overall
survival. ST2, IL2Ra, and TNFR1 biomarker levels were
signiﬁcantly elevated in, but not speciﬁc to, ES. Despite high-
dose steroids to manage ES, outcomes remained poor. Future
studies should include prospective collection of clinical fea-
tures combinedwith correlative laboratory analyses to better
characterize ES.
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